AAV5 Capsid Variants Evading Antibody Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering gene therapy to the central nervous system (CNS) face challenges due to low transduction efficiency of natural adeno-associated virus (AAV) variants and neutralization by pre-existing antibodies, limiting their clinical application.
Innovation Solution
Development of AAV capsid variants, such as AAV5 capsid variants, with specific amino acid modifications at position 577, including substitutions like Y, N, or C, to enhance tropism for CNS and other tissues, thereby improving delivery efficiency and evading neutralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural AAV variants are used for CNS delivery, then the transduction efficiency is improved, but the neutralization by pre-existing antibodies increases
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at defined positions (e.g., position 577) of the AAV5 capsid protein while maintaining the overall capsid structure. This localized modification approach allows the capsid to evade neutralization by pre-existing antibodies while preserving transduction efficiency in CNS tissues.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid sequences at specific positions of the AAV5 capsid to generate variants with improved properties. The substitutions at position 577 and other positions create capsid variants that alter immune recognition while maintaining or enhancing CNS tropism and transduction efficiency.
2Reliability
If AAV capsid variants with improved CNS tropism are developed, then the delivery efficiency to CNS is improved, but the complexity of capsid engineering increases
Solution Approach 1:
The patent applies segmentation by focusing engineering efforts on specific regions of the capsid protein (P2 and P3 domains, particularly position 577) rather than attempting to optimize the entire capsid structure. This segmented approach simplifies the engineering process while achieving improved CNS delivery efficiency.
Solution Approach 2:
The patent uses parameter changes by systematically modifying amino acid sequences at specific positions to generate a library of capsid variants. This approach allows for rational design and screening of variants with improved CNS tropism while maintaining a manageable level of engineering complexity through focused mutagenesis strategies.
Data Source
AI summary
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.